AR047128A1 - Composiciones farmaceuticas que contienen derivados de tiazolidin-4-ona, procesos de preparacion y uso como agentes inmunosupresores - Google Patents

Composiciones farmaceuticas que contienen derivados de tiazolidin-4-ona, procesos de preparacion y uso como agentes inmunosupresores

Info

Publication number
AR047128A1
AR047128A1 ARP040104281A ARP040104281A AR047128A1 AR 047128 A1 AR047128 A1 AR 047128A1 AR P040104281 A ARP040104281 A AR P040104281A AR P040104281 A ARP040104281 A AR P040104281A AR 047128 A1 AR047128 A1 AR 047128A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
represents hydrogen
mixtures
independently
tiazolidin
Prior art date
Application number
ARP040104281A
Other languages
English (en)
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34639216&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR047128(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of AR047128A1 publication Critical patent/AR047128A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)

Abstract

Reivindicacion 1: Composicion farmacéutica que contiene por lo menos un derivado de tiazolidin-4-ona de formula general (1), en la cual: R1 representa alquilo inferior, alquenilo inferior; cicloalquilo; 5,6,7,8-tetrahidronaft-1-ilo; 5,6,7,8- tetrahidronaft-2-ilo; un grupo fenilo; un grupo fenilo independientemente mono-, di- o trisustituido con alquilo inferior, halogeno, alcoxi inferior o -CF3; R2 representa alquilo inferior; alilo; ciclopropilo; ciclobutilo; ciclopentilo; mono- o dialquilamino inferior; R3 representa -NR5R6; -O-CR7R6-CR9R10-(CR11R12)n-O-R13; R4 representa hidrogeno; hidroxi; alcoxi inferior; alquilo inferior; halogeno; o R3 y R4 juntos pueden formar un anillo metilendioxi o etilendioxi opcionalmente sustituidos además con un grupo hidroximetilo; R5 y R6 representa cada uno independientemente alquilo inferior; R7 representa hidrogeno, alquilo inferior o hidroximetilo; R8, R9, R11 y R12 representa cada uno independientemente hidrogeno o metilo; R10 representa hidrogeno o alquilo inferior; en caso que n represente el numero entero 1, R10 representa además alcoxi inferior, hidroxi, -NH2, -NHR1 o -NR5R6; R13 representa hidrogeno; alquilo inferior; hidrocarbonil-alquilo inferior; 1-glicerilo o 2-glicerilo; n representa el numero entero 0 o 1; e isomeros configuracionales, enantiomeros opticamente puros, mezclas de enantiomeros tales como racematos, diastereomeros, mezclas de diastereomeros, racematos diaesteroméricos, mezclas de racematos diastereoméricos y la mesoforma, así como sales aceptables para uso farmacéutico, complejos con solventes y formas morfologicas, y materiales como vehículos inertes.
ARP040104281A 2003-11-21 2004-11-19 Composiciones farmaceuticas que contienen derivados de tiazolidin-4-ona, procesos de preparacion y uso como agentes inmunosupresores AR047128A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP0313072 2003-11-21

Publications (1)

Publication Number Publication Date
AR047128A1 true AR047128A1 (es) 2006-01-11

Family

ID=34639216

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104281A AR047128A1 (es) 2003-11-21 2004-11-19 Composiciones farmaceuticas que contienen derivados de tiazolidin-4-ona, procesos de preparacion y uso como agentes inmunosupresores

Country Status (26)

Country Link
US (8) USRE43728E1 (es)
EP (2) EP1689726B1 (es)
JP (2) JP4061332B2 (es)
KR (1) KR100783835B1 (es)
CN (1) CN100567275C (es)
AR (1) AR047128A1 (es)
AT (1) ATE483698T1 (es)
AU (1) AU2004295047B2 (es)
BR (1) BRPI0416752B8 (es)
CA (1) CA2545582C (es)
CY (1) CY1111087T1 (es)
DE (1) DE602004029493D1 (es)
DK (1) DK1689726T3 (es)
ES (1) ES2352555T3 (es)
HR (1) HRP20100714T1 (es)
IL (1) IL175758A (es)
MY (1) MY145074A (es)
NO (1) NO336734B1 (es)
NZ (1) NZ547962A (es)
PL (1) PL1689726T3 (es)
PT (1) PT1689726E (es)
RU (1) RU2379299C2 (es)
SI (1) SI1689726T1 (es)
TW (1) TWI323659B (es)
WO (1) WO2005054215A1 (es)
ZA (1) ZA200605077B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004295047B2 (en) 2003-11-21 2011-03-10 Actelion Pharmaceuticals Ltd 5-(benz- (Z) -ylidene) -thiazolidin-4-one derivatives as immunosuppressant agents
USRE43833E1 (en) 2003-11-21 2012-11-27 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
JP2007523957A (ja) * 2004-02-25 2007-08-23 スミスクライン・ビーチャム・コーポレイション 新規化学化合物
RU2007109207A (ru) 2004-08-13 2008-09-20 Прикис Фамэсьютикэлс, Инк. (US) Соединения-модуляторы активности рецептора сфингозин-1-фосфата (варианты), фармацевтическая композиция, содержащая указанные соединения, и способ лечения нарушения, ассоциированного со сфингозин-1-фосфатом
EP1959958A4 (en) * 2005-11-14 2010-07-14 Univ Southern California INTEGRIN-BINDING SMALL MOLECULES
JP4182986B2 (ja) * 2006-04-19 2008-11-19 トヨタ自動車株式会社 半導体装置とその製造方法
US8912340B2 (en) 2006-11-23 2014-12-16 Actelion Pharmaceuticals Ltd. Process for the preparation of 2-imino-thiazolidin-4-one derivatives
ES2523401T3 (es) * 2006-11-23 2014-11-25 Actelion Pharmaceuticals Ltd. Intermedios de un nuevo procedimiento para la preparación de derivados de 5-benciliden-2-alquilimino-3- feniltiazolidin-4-ona
CN101980704A (zh) * 2008-03-17 2011-02-23 埃科特莱茵药品有限公司 选择性s1p1受体激动剂的给药方案
GB0819182D0 (en) * 2008-10-20 2008-11-26 Actelion Pharmaceuticals Ltd Crystalline forms
JP2013533286A (ja) 2010-07-30 2013-08-22 セントルイス ユニバーシティ 疼痛を治療する方法
CA2895172C (en) * 2012-08-17 2020-08-18 Actelion Pharmaceuticals Ltd Process for the preparation of|(2z,5z)-5-(3-chloro-4-((r)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-|(o-tolyl)thiazolidin-4-one and intermediate used in said process
JP6294872B2 (ja) 2013-04-26 2018-03-14 国立大学法人京都大学 脳動脈瘤の形成および／または増大の抑制若しくは縮小用医薬組成物
EP2862574A1 (en) 2013-10-15 2015-04-22 Sanofi {4-[5-(3-chloro-phenoxy)-oxazolo[5,4 d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid for use in the prevention or treatment of acute kidney injury
US10155754B2 (en) 2014-05-28 2018-12-18 Universitat Bern Substituted 2-imino-1,3-thiazolidin-4-ones as N-arachidonoylethanolamine cellular uptake inhibitors
EP2952188A1 (en) * 2014-06-03 2015-12-09 Universität Bern Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation
US10300048B2 (en) 2014-05-28 2019-05-28 Universitat Bern Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation
MX2020011182A (es) 2014-12-11 2022-10-03 Actelion Pharmaceuticals Ltd Regimen de dosificacion para un agonista selectivo de receptor s1p1.
MA41139A (fr) 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
US10111841B2 (en) 2015-06-19 2018-10-30 University Of South Florida Stabilization of alcohol intoxication-induced cardiovascular instability
MX2018007887A (es) 2015-12-25 2019-02-20 Crystal Pharmatech Co Ltd Formas cristalinas de modulador selectivo del receptor s1p1 y método de preparación del mismo.
JOP20190207A1 (ar) 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود
US11220488B2 (en) 2017-09-19 2022-01-11 Teva Pharmaceuticals International Gmbh Crystalline polymorph of Ponesimod
TWI647229B (zh) 2017-11-14 2019-01-11 國立暨南國際大學 Method for synthesizing 3,4-hydroisoquinoline thiazolidine
US11014897B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof
US11013723B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms of a thiazolidinone compound, compositions and methods of use thereof
US11186556B1 (en) 2018-10-16 2021-11-30 Celgene Corporation Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
US11014940B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Thiazolidinone and oxazolidinone compounds and formulations
AU2020372647A1 (en) 2019-10-31 2022-06-16 Idorsia Pharmaceuticals Ltd Combination of a CXCR7 antagonist with an S1P1 receptor modulator
AR121276A1 (es) 2020-02-06 2022-05-04 Mitsubishi Tanabe Pharma Corp Agente terapéutico para la encefalomielitis miálgica / síndrome de fatiga crónica
WO2023022896A1 (en) 2021-08-17 2023-02-23 Teva Czech Industries S.R.O Polymorphs of ponesimod
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator
WO2023152691A1 (en) * 2022-02-10 2023-08-17 Metrochem Api Pvt Ltd Process for the preparation of ponesimod and its intermediates thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3077402A (en) 1954-12-06 1963-02-12 Polaroid Corp Photographic color processes, products, and compositions
NL270002A (es) 1960-10-08
OA03835A (fr) 1970-07-17 1971-12-24 Rhone Poulenc Sa Nouveaux dérivés de la thiazolidine, leur préparation et les compositions qui les contiennent.
EP0526598B1 (en) 1990-04-27 1996-12-18 Orion-Yhtymà„ Oy New pharmacologically active catechol derivatives
TW221689B (es) 1991-08-27 1994-03-11 Otsuka Pharma Co Ltd
CA2134347C (en) 1993-02-26 2003-04-29 Koichi Yasumura Thiazole or imidazole derivatives as maillard reaction inhibitors
KR960022486A (ko) 1994-12-29 1996-07-18 김준웅 신규 티아졸리딘-4-온 유도체
US6353006B1 (en) 1999-01-14 2002-03-05 Bayer Corporation Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
ATE393150T1 (de) * 1999-09-14 2008-05-15 Shionogi & Co 2-imino-1,3-thiazin-derivate
DE69934027T2 (de) 1999-11-12 2007-06-21 Fujimoto Brothers Co., Ltd., Matubara 2-(n-cyanimino)thiazolidin-4-on derivate
US20050019825A9 (en) * 2002-03-15 2005-01-27 Qing Dong Common ligand mimics: pseudothiohydantoins
BR0312752A (pt) * 2002-07-10 2005-04-26 Applied Research Systems Derivados de benzeno fundido de azolidinona-vinil
GB0217152D0 (en) 2002-07-24 2002-09-04 Novartis Ag Organic compounds
WO2004014313A2 (en) 2002-08-12 2004-02-19 Bristol-Myers Squibb Company Combination pharmaceutical agents as inhibitors of hcv replication
AU2003298693B2 (en) 2002-11-22 2010-09-30 Smithkline Beecham Corporation Novel chemical compounds
US20040167192A1 (en) * 2003-01-16 2004-08-26 David Solow-Cordero Methods of treating conditions associated with an Edg-7 receptor
AU2004295047B2 (en) 2003-11-21 2011-03-10 Actelion Pharmaceuticals Ltd 5-(benz- (Z) -ylidene) -thiazolidin-4-one derivatives as immunosuppressant agents
USRE43833E1 (en) 2003-11-21 2012-11-27 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
JP2007523957A (ja) 2004-02-25 2007-08-23 スミスクライン・ビーチャム・コーポレイション 新規化学化合物
WO2006094233A1 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. N,n'-dicyclic isothiourea sirtuin modulators
ES2523401T3 (es) 2006-11-23 2014-11-25 Actelion Pharmaceuticals Ltd. Intermedios de un nuevo procedimiento para la preparación de derivados de 5-benciliden-2-alquilimino-3- feniltiazolidin-4-ona
US8912340B2 (en) 2006-11-23 2014-12-16 Actelion Pharmaceuticals Ltd. Process for the preparation of 2-imino-thiazolidin-4-one derivatives
CN101980704A (zh) 2008-03-17 2011-02-23 埃科特莱茵药品有限公司 选择性s1p1受体激动剂的给药方案
GB0819182D0 (en) 2008-10-20 2008-11-26 Actelion Pharmaceuticals Ltd Crystalline forms

Also Published As

Publication number Publication date
HRP20100714T1 (hr) 2011-01-31
IL175758A0 (en) 2006-09-05
TWI323659B (en) 2010-04-21
PT1689726E (pt) 2010-12-09
CN100567275C (zh) 2009-12-09
TW200528097A (en) 2005-09-01
EP2295418A1 (en) 2011-03-16
AU2004295047B2 (en) 2011-03-10
CA2545582C (en) 2013-04-16
JP2008081504A (ja) 2008-04-10
BRPI0416752B1 (pt) 2019-11-05
ATE483698T1 (de) 2010-10-15
AU2004295047A1 (en) 2005-06-16
ZA200605077B (en) 2007-05-30
BRPI0416752A (pt) 2007-02-27
US20120302612A1 (en) 2012-11-29
CY1111087T1 (el) 2015-06-11
EP1689726A1 (en) 2006-08-16
US7875726B2 (en) 2011-01-25
WO2005054215A1 (en) 2005-06-16
CA2545582A1 (en) 2005-06-16
US8524752B2 (en) 2013-09-03
US20080146629A1 (en) 2008-06-19
JP4061332B2 (ja) 2008-03-19
US7626037B2 (en) 2009-12-01
BRPI0416752B8 (pt) 2021-05-25
ES2352555T3 (es) 2011-02-21
SI1689726T1 (sl) 2011-01-31
KR20060117328A (ko) 2006-11-16
US20070082933A1 (en) 2007-04-12
US20090275625A1 (en) 2009-11-05
USRE43728E1 (en) 2012-10-09
IL175758A (en) 2012-10-31
US20080280962A1 (en) 2008-11-13
PL1689726T3 (pl) 2011-05-31
CN1882555A (zh) 2006-12-20
DE602004029493D1 (de) 2010-11-18
RU2379299C2 (ru) 2010-01-20
US20130310432A1 (en) 2013-11-21
NZ547962A (en) 2010-06-25
US7435828B2 (en) 2008-10-14
JP4129286B2 (ja) 2008-08-06
KR100783835B1 (ko) 2007-12-10
JP2007511563A (ja) 2007-05-10
NO20062483L (no) 2006-08-10
DK1689726T3 (da) 2010-12-06
EP1689726B1 (en) 2010-10-06
USRE45174E1 (en) 2014-09-30
US8273779B2 (en) 2012-09-25
RU2006121651A (ru) 2008-01-10
US9000018B2 (en) 2015-04-07
NO336734B1 (no) 2015-10-26
MY145074A (en) 2011-12-15

Similar Documents

Publication Publication Date Title
AR047128A1 (es) Composiciones farmaceuticas que contienen derivados de tiazolidin-4-ona, procesos de preparacion y uso como agentes inmunosupresores
AR053845A1 (es) 5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450
UY27388A1 (es) Nuevos compuestos
CR9459A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
AR056347A1 (es) Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas
AR072488A1 (es) Derivados heterociclicos de 1,2,4-triazol, agonistas de receptores beta 2 adrenergicos y antagonistas muscarinicos colinergicos, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento de afecciones respiratorias, inflamatorias y alergicas.
AR058699A1 (es) Derivados de sulfonamidoanilina como inhibidores de tirosina-quinasas jak-2 y jak-3
AR058073A1 (es) Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos
AR051997A1 (es) Heterociclos triciclicos, su obtencion y uso delos mismos c omo agentes farmaceuticos
AR047466A1 (es) Compuestos derivados de 3h - imidazo[4,5 - b]piridina con actividad inhibidora de quinasa, composiciones farmacéuticas que los contienen como principio activo y su uso en la fabricacion de un medicamento para el tratatmiento de neoplasmas susceptibles.
ECSP045003A (es) Nuevas dihidro-pteridinonas, procedimientos para su preparación y su utilización como medicamentos.
AR063022A1 (es) Derivados de indol antagonistas del receptor de glucagon, composiciones farmaceuticas que los contienen y usos para tratar diabetes mellitus tipo 2 y estados patologicos relacionados.
SV2005001920A (es) " compuestos nucleosidos para el tratamiento de infecciones virales "
AR053195A1 (es) Compuestos inhibidores de dipeptidil peptidasa-iv metodos para preparar los mismos y composiciones farmaceuticas que los contienen como un agente activo
AR043434A1 (es) Derivados de piperizacina acilados como agonistas del receptor de melanocortina-4. composiciones farmaceuticas y usos
AR056511A1 (es) Derivados de 2-aminopirimidinas, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor de histamina h4
AR078152A1 (es) Compuestos heterociclicos, utiles para el tratamiento de hcv y composiciones farmaceuticas que los comprenden
AR048004A1 (es) Nuevos esteres de quinuclidina cuaternizados
AR063119A1 (es) Derivados de piridinonas sustituidas, composiciones farmaceuticas que los contienen y usos como antagonistas en trastornos asociados a receptores del tipo i de la hormona de melanina(mch-1 o mchr-1)
AR048607A1 (es) Derivados (poli)aminoalquilaminoacetamida de la epipodofilotoxina, proceso de preparacion de los mismos y sus aplicaciones terapeuticas como agentes anticancerosos
AR045155A1 (es) Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos
AR045999A1 (es) Compuesto de eter de piperidina, su uso para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para prepararlo
PE20212327A1 (es) Ciertos compuestos de pladienolida y metodos de uso
AR053835A1 (es) Tetrahidropiridoazepin - 8 - onas como moduladores del receptor de dopamina d2 y compuestos relacionados para el tratamiento de la esquizofrenia y otros trastornos del snc, composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos.
AR045156A1 (es) Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos

Legal Events

Date Code Title Description
FG Grant, registration